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Abstract
Purpose of review—Elucidating the genetic background of Parkinson disease and essential
tremor is crucial to understand the pathogenesis and improve diagnostic and therapeutic strategies.
Recent findings—A number of approaches have been applied including familial and
association studies, and studies of gene expression profiles to identify genes involved in
susceptibility to Parkinson disease. These studies have nominated a number of candidate
Parkinson disease genes and novel loci including Omi/HtrA2, GIGYF2, FGF20, PDXK, EIF4G1
and PARK16. A recent notable finding has been the confirmation for the role of heterozygous
mutations in glucocerebrosidase (GBA) as risk factors for Parkinson disease. Finally, association
studies have nominated genetic variation in the leucine-rich repeat and Ig containing 1 gene
(LINGO1) as a risk for both Parkinson disease and essential tremor, providing the first genetic
evidence of a link between the two conditions.
Summary—Although undoubtedly genes remain to be identified, considerable progress has been
achieved in the understanding of the genetic basis of Parkinson disease. This same effort is now
required for essential tremor. The use of next-generation high-throughput sequencing and
genotyping technologies will help pave the way for future insight leading to advances in diagnosis,
prevention and cure.
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Introduction
Parkinson disease and essential tremor are prevalent age-related conditions whose clinical
manifestations worsen over time, eventually impacting on patients’ quality of life [1,2].
Even though Parkinson disease and essential tremor are traditionally viewed as sporadic
diseases, about 15% of patients with Parkinson disease report an affected first-degree
relative, and up to 50% of cases with essential tremor display familial aggregation [3,4].
Individuals with Parkinson disease present with various combinations of motor (rest tremor,
bradykinesia, rigidity and postural instability) and nonmotor (hyposmia, autonomic
dysfunction, sleep disorders, cognitive impairment and depression) symptoms, whereas the
main clinical feature in essential tremor consists of action (postural and kinetic) tremor.
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Motor symptoms respond to dopaminergic agents (Parkinson disease) and various
pharmacologic treatments including beta-blockers (essential tremor), and are amenable to
surgical treatment with deep-brain stimulation (Parkinson disease and essential tremor).
Despite therapeutic advances aimed at symptomatic control, no proven treatment currently
exists that alters the course or prevents the occurrence of either Parkinson disease or
essential tremor. Understanding the genetic basis of disease may provide us with the
knowledge and tools to design future therapeutic strategies targeting the very molecular
events leading to neuronal loss/dysfunction. The purpose of this review is to discuss recent
advances in the genetics of Parkinson disease and essential tremor, as well as their
significance for future research.
Causal mutations and risk-modifying variants in Parkinson disease
Since the discovery of the first disease-causing mutation in the α-synuclein gene (SNCA), a
number of genes and loci have been implicated in Parkinson disease (Table 1). Those genes
harboring mutations that cause late-onset dominantly inherited Parkinson disease include
SNCA and leucine-rich repeat kinase 2 (LRRK2), whereas early-onset recessive
parkinsonism is associated with homozygous and compound heterozygous mutations in
parkin (PRKN), Pten-induced kinase 1 (PINK1) and Oncogene DJ-1 (DJ-1) [5]. Of note,
these genes were identified by family-based ‘traditional’ linkage studies, whereas large
population-based genome-wide association studies (GWAS) have been largely confirmatory
so far (see below).
Despite their importance in identifying key players in the pathogenesis of Parkinson disease,
mutations in those genes associated with Mendelian-inherited disease remain relatively rare
and account for only a fraction of familial cases. However, there are marked population-
specific differences, for example the most common LRRK2 mutation in populations of
European descent (Lrrk2 p.G2019S) causes late-onset Parkinson disease that is clinically
similar to idiopathic Parkinson disease [6•]. Prevalence rates of Lrrk2 p.G2019S in
Parkinson disease range from 1–2% (sporadic patients) to 4–5% (familial patients) in
populations of European descent, whereas figures rise to 30–40% among North African
Arabs and Ashkenazi Jews, and the mutation is virtually absent in Asians [6•,7–10]. By
contrast, two coding variants in Lrrk2 (p.G2385R and p.R1628P) have been shown to
significantly alter risk for Parkinson disease, however, only in populations of Asian descent,
further emphasizing differences due to ethnicity [11–17,18•]. Although over 100 variants
have been identified in the LRRK2 gene, pathogenicity had been established for only six
causal mutations (p.R1441C, p.R1441G, p.R1441H, p.G2019S, p.I2020T and p.Y1699C)
and two risk factors (p.G2385R and p.R1628P) [19]. Recently, however, a novel pathogenic
coding mutation (p.N1437H) was identified to segregate with disease in a large Norwegian
family with dominantly inherited, early-onset Parkinson disease [20•]. The Lrrk2 p.N1437H
mutation was also identified in one other Norwegian patient with familial Parkinson disease
and not in 623 controls. Additionally, in-vitro evidence showed the Lrrk2 p.N1437H
mutation enhances GTP-binding and kinase activity, which further supports pathogenicity.
Perhaps one of the most surprising findings has been the discovery that heterozygous
mutations in the glucocerebrosidase gene (GBA) significantly alter risk for sporadic and
familial Parkinson disease as well as for diffuse Lewy body disease [21–24]. Homozygous
or compound heterozygous mutations in GBA cause Gaucher’s disease which does not share
clinical or pathological features with Parkinson disease. A recent multicenter collaborative
study that included 5691 patients with Parkinson disease and 4898 controls from Europe, the
US, Israel and Asia found much higher rates of GBA mutations among patients with
Parkinson disease (15% in Ashkenazi Jews, 3% in non-Ashkenazi Jews) compared with
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controls (Ashkenazi Jews: 3%; non-Ashkenazi Jews: <1%) [25••]. This study demonstrates
that GBA mutations represent a rather strong [odds ratio (OR) ~10–15] risk factor for
Parkinson disease particularly prevalent among Ashkenazi Jews, but also present in
populations of European and Asian descent.
In addition to risk-modifying variants and mutations in LRRK2 and GBA, the most robust
and consistent associations with Parkinson disease have been with SNCA and microtubule-
associated protein tau (MAPT) [26,27]. The fact that mutations in LRRK2, SNCA and MAPT
also cause dominantly inherited forms of parkinsonism emphasizes the importance of
studying monogenic forms in order to understand the pathogenesis of Parkinson disease. It
also indicates that genetic factors determine both sporadic and familial forms of Parkinson
disease, and that the degree of disease heritability depends on the combination and
penetrance of such variants. One noteworthy study of SNCA multiplication patients in Japan
demonstrated that reduced penetrance is also a feature of this form of parkinsonism and
reminds us that age remains the greatest risk factor for late-onset neurodegenerative
disorders such as Parkinson disease and essential tremor [28•].
Linkage, association and expression: different paths to the same goal
At the 18th WFN World Congress on Parkinson’s Disease and Related Disorders held in
Miami, FL (USA) in December 2009, a presentation by Dr Matthew J. Farrer of the Mayo
Clinic announced the discovery of a mutation (p.R1205H) in eukaryotic translation
initiation factor 4G1 (EIF4G1) that segregates with disease in a large French family with
autosomal dominant, late-onset Parkinson disease [29•]. The p.R1205H mutation was also
found in three smaller families from Ireland, Italy and the US but not in 4000 control
individuals. Whereas these findings clearly warrant replication, EIF4G1 may represent yet a
novel gene implicated in Parkinson disease. The eIF4G1 protein helps regulate translation of
specific mRNAs in response to stress, growth factors and nutrient availability. Generally,
depletion of eIF4G1 impairs nutrient sensing and mitochondrial bioenergetics while
promoting autophagy, which would complement known mechanisms in Parkinson disease
pathogenesis.
Recently, Elstner and colleagues [30•] reported an association between genetic variation in
the pyridoxal kinase gene (PDXK) and risk for Parkinson disease. They used an innovative
approach by examining the whole-genome expression profile in isolated cells from the
substantia nigra in patients with Parkinson disease and controls, followed by an association
study. However, a replication study in six independent patient–control series of European
ancestry (n =3884) could not confirm an association with risk for Parkinson disease;
therefore further studies are required to establish the role of PDXK in Parkinson disease
[31].
An association between variation in the fibroblast growth factor 20 gene (FGF20) and risk
for Parkinson disease was reported in populations of European and Asian descent [32,33].
Furthermore, in-vitro evidence suggested that FGF20 SNP rs12720208 modifies risk of
Parkinson disease by disrupting a micro-RNA (miRNA-433) binding site, thereby altering
levels of the FGF20 and α-synuclein proteins [32]. However, replication studies have failed
to confirm the association as well as the effect on levels of α-synuclein [34–36]. Mutations
in the Omi/HtrA2 gene (PARK13) had previously been implicated in Parkinson disease
[37,38]; however, a large replication study performed by the GEO-PD consortium on 6378
patients and 8880 controls failed to identify an association with risk for Parkinson disease
[39], supporting earlier studies [40,41]. Mutations in the GIGYF2 gene were suggested to
account for linkage within the PARK11 locus [42]. A remarkable effort was put into trying
to replicate and extend these findings, yet studies performed in several populations of
European and Asian descent, including those patients in which the PARK11 locus was
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originally identified, have largely disproved this hypothesis and shown GIGYF2 variants are
unlikely to play a role in Parkinson disease susceptibility [43–46].
Genome-wide association studies in Parkinson disease
Genome-wide association studies have emerged as a powerful and unbiased analysis tool
utilizing high-density single-nucleotide polymorphism (SNP) chips. However, early findings
in Parkinson disease have fallen short of expectations with the identification of known
Parkinson disease genes/loci, or the nomination of novel genes/loci subsequently not
replicated [36,47,48]. Possible explanations for these results include heterogeneity of
Parkinson disease, sample size issues, and the fact that only common variants are examined
that have to be highly correlated (i.e. in high degree of linkage disequilibrium) with disease-
associated variants in order to be identified.
Recently two large GWAS in Parkinson disease have been completed in populations of
European and Asian descent [49••,50••]. Simon-Sanchez and colleagues [49••] examined a
series of 1713 patients and 3978 controls of European ancestry in the GWAS phase (3452
patients and 4756 controls for subsequent replication) and found genome-wide significant
associations with Parkinson disease for only two previously identified loci, SNCA and
MAPT. The study by Satake and colleagues [50••] included 1078 patients and 2628 controls
from Japan in the GWAS phase, and two independent sets for replication (combined: 937
patients and 15 753 controls). The combined analysis of all Japanese series identified four
loci that associated with Parkinson disease at the genome-wide level, including SNCA; one
novel locus on 1q32 (designated PARK16); a second novel locus on 4p15 that contains one
gene (BST1); and one locus on 12q12 (upstream from LRRK2) [50••]. Replication attempts
in the European series found nominal significance for disease association with PARK16,
supporting it as being a potential risk factor for Parkinson disease in both Asian and
European populations [49••]. In contrast, there was no association with the 4p15 locus in the
European series. As expected no association with MAPT was observed in the Japanese series
(the MAPT H2 allele is on the whole absent in Asian populations), further emphasizing
population-specific differences in genetic factors implicated in Parkinson disease.
Linkage, genome-wide association studies and the genetic factors
implicated in essential tremor
Despite its high prevalence and degree of inheritability, essential tremor has proven more
challenging than Parkinson disease with regard to the identification of its genetic
determinants. This may in part reflect methodological issues relating to the lack of a reliable
diagnostic biomarker. Three loci (ETM1, ETM2 and ETM3) were nominated through
genome-wide linkage studies in families with essential tremor. However, no mutation has
been replicated in candidate genes within these loci, including dopamine D3 receptor
(DRD3) and HS1-binding protein 3 (HS1BP3) [51].
Last year, Stefansson and colleagues [52••] completed the first GWAS in essential tremor,
using an Icelandic series of 452 patients and 14 378 controls (discovery phase). Two SNPs
located in intron 3 of the leucine-rich repeat and Ig domain containing 1 gene (LINGO1)
displayed nominal association with risk for essential tremor. When combining the discovery
and replication samples (752 patients and 15 797 controls from Iceland, Austria, Germany
and the US) the authors found a genome-wide significant association between LINGO1 SNP
rs9652490 and risk for essential tremor. We and others confirmed this finding in populations
of European and Asian descent, showing LINGO1 is likely a risk factor for essential tremor
with widespread distribution [53•,54]. Furthermore, an extended multicenter study
investigating LINGO1 and its paralog LINGO2 by means of gene sequencing and an
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association study using haplotype-tagging SNPs distributed across both genes identified six
novel coding variants in LINGO1 and LINGO2 that may be pathogenic, as well as
polymorphisms nominally associated with risk for essential tremor [55]. These findings
warrant further studies to establish the role of LINGO1 and LINGO2 in essential tremor,
identify the variants/mutations responsible for the association and understand the pathogenic
mechanisms involved.
Parkinson disease and essential tremor: is there a connection?
Whereas Parkinson disease and essential tremor are rightfully regarded as distinct entities,
clinical evidence suggests there is considerable overlap, including a fourfold increase in risk
of Parkinson disease in patients with essential tremor, the presence of action tremor often
preceding the onset of Parkinson disease symptoms, and an increased prevalence of essential
tremor in relatives of patients with Parkinson disease [56]. Additionally, brainstem Lewy
bodies have been identified in a number of essential tremor cases, and imaging studies have
found signs of dopaminergic deficiency in some patients with essential tremor [57].
Therefore we investigated the role of LINGO1 in Parkinson disease by genotyping
rs9652490 in 1044 patients with Parkinson disease of Caucasian ancestry (426 from North
America and 618 from Norway) and in 1030 ethnically and sex-matched controls. An
association between rs9652490 and risk for Parkinson disease was identified in the US and
Norwegian populations as well as in the combined series [OR 1.8; 95% confidence interval
(CI) 1.3–2.7] [53•]. Given the association of LINGO1 with risk for essential tremor, this
provides the first evidence of a genetic link between Parkinson disease and essential tremor
and opens new avenues in the understanding of mechanisms implicated in both conditions.
Our follow-up study extended this observation to other variants in LINGO1 as well as in its
paralog LINGO2, and identified additional polymorphisms nominally associated with risk
for Parkinson disease and essential tremor [55]. Two subsequent studies investigated the role
of LINGO1 in Parkinson disease in populations from Austria and Poland [58,59]. Whereas
both studies performed on relatively small samples did not confirm an association with risk
of Parkinson disease, a meta-analysis supported a role for LINGO1 in Parkinson disease
[58]. Therefore these negative results may relate to power issues and further studies of larger
populations are warranted to investigate the role of LINGO1 in Parkinson disease.
The way ahead
Despite recent progress in unraveling the genetic factors that determine risk for Parkinson
disease and essential tremor, mutations and variation in known genes account for only a
fraction of the genetic risk and more genes remain likely to be identified. Apart from the
recently nominated loci (PARK16 and 4p15) which await confirmation, GWAS have fallen
short of identifying novel genes and loci in Parkinson disease. It has been suggested that
complex traits such as Parkinson disease and essential tremor may be influenced by the
combined effect of rare variants rather than by a few common variants [60–62]. Therefore
approaches that detect rare variants may be needed, which include high-throughput next-
generation sequencing of all exons within genome (exome sequencing) or the whole genome
itself. Sequencing technology for this is readily available and rapid reduction of costs will
soon allow performing studies on a large scale, which will likely help expand our knowledge
of the genetic background of Parkinson disease and essential tremor.
Conclusion
Over a decade after the discovery that mutations in SNCA cause Parkinson disease,
tremendous progress has been achieved that has shed light on molecular mechanisms
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implicated in Parkinson disease and less so for essential tremor. However, more effort needs
to be put into collecting large samples of familial and sporadic patients from different
ethnicities, in order to further understand disease pathogenesis. With the use of novel
technologies we will likely see more genes being identified that will pave the way for future
targeted therapeutics aimed at disease prevention and cure.
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Table 1
Genes implicated in monogenic forms of Parkinson disease and parkinsonism-plus syndromes
Gene Locus/disease Mode of inheritance Phenotype Onset age (years)
SNCA PARK1/4 AD PD, PDD, DLB 20–85
PRKN PARK2 AR EOPD 16–72 (mean 30)
PINK1 PARK6 AR EOPD 20–40
DJ1 PARK7 AR EOPD 20–40
LRRK2 PARK8 AD PD 32–79
ATP13A2 PARK9/KRS AR P, D, O, S 11–16
NR4A2/NURR1 – Unknown PD 45–67
POLG – Unknown PD 20–26
FBXO2 PARK15/PPS AR P, S 10–19
GRN FTDP-17 AD FTD, FTD-MND, P, CBS 45–83
MAPT FTDP-17 AD FTD, P, O, CBS 25–76
DCTN1 Perry syndrome AD P, Dep, H, WL 35–61
AD, autosomal dominant; AR, autosomal recessive; CBS, cortico-basal syndrome; D, dementia; Dep, depression; DLB, dementia with Lewy
bodies; EOPD, early-onset Parkinson disease; FTD, frontotemporal dementia; FTD-MND, frontotemporal dementia – motor neuron disease;
FTDP-17, frontotemporal dementia with parkinsonism linked to chromosome 17; H, hypoventilation; KRS, Kufor-Rakeb syndrome; O, oculomotor
signs; P, parkinsonism; PD, Parkinson disease (dopa-responsive parkinsonism); PDD, Parkinson disease – dementia; PPS, pallido-pyramidal
syndrome; S, spasticity; WL, weight loss.
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